[Skip to Navigation]
Views 709
Citations 0
Comment & Response
April 16, 2020

Defining the Right State for a Will Rogers Phenomenon in Oligometastatic Prostate Cancer

Author Affiliations
  • 1Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • 2Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • 3Vita-Salute San Raffaele University, Milan, Italy
JAMA Oncol. 2020;6(6):936-937. doi:10.1001/jamaoncol.2020.0574

To the Editor In a recent Viewpoint, Connor et al1 discussed diagnosis and risk classification in men with oligometastatic prostate cancer. They hypothesized that the diagnostic superiority of novel targeted imaging in detection of metastatic disease would allow early identification of oligometastatic prostate cancer, generating a stage migration and a so-called Will Rogers phenomenon for the survival of these patients.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Can we have a win win approach with prostate cancer?
    David Bryant, MD | Ascension Via Christi Cancer Center Wichita Kansas
    1. Can we cut the number of deaths from prostate cancer in half? AND
    2. Can we cut the number of side effects from diagnostic evaluations and treatment in half? AND
    3. Can we improve the quality of life by a factor of 2 over a person's life? AND
    4. Can we cut the cost of prostate cancer care in half?
    5. Once we fulfill 1-4, can we start at 1?

    I think every paper on prostate cancer should address each of these questions. Rarely will a paper discuss two of the questions. We really dislike talking about question
    number 4.
    If we put our minds together, doctors and patients can solve these problems.